Seres Therapeutics Inc. (MCRB)
NASDAQ:MCRB
Want to see MCRB full AI Analyst Report?
MCRB Stock Chart & Stats
$8.89
>-$0.01(-0.25%)
At close: 4:00 PM EST
$8.89
>-$0.01(-0.25%)
Day’s Range― - ―
52-Week Range$6.32 - $29.98
Previous CloseN/A
Volume457.00K
Average Volume (3M)57.17K
Market Cap
$64.20M
Enterprise Value$121.55M
Total Cash (Recent Filing)$29.83M
Total Debt (Recent Filing)$80.50M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 05, 2026EPS Estimate
-2.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.18
Shares Outstanding9,683,934
10 Day Avg. Volume71,507
30 Day Avg. Volume57,171
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)2.98
Price to Sales (P/S)167.07
P/FCF Ratio152.39
Enterprise Value/Market Cap1.89
Enterprise Value/Revenue105.97
Enterprise Value/Gross Profit-506.46
Enterprise Value/Ebitda-2.59
Forecast
1Y Price Target
$22.00Price Target Upside147.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-8.23
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Milestone Buyout Improves LiquidityA $25M non-dilutive milestone buyout materially improves near-term liquidity and extends the cash runway into Q1 2027. This reduces immediate reliance on equity raises, lowers financing pressure, and gives management time to advance clinical programs or seek strategic partnerships.
Lease Restructuring Cuts Fixed CostsThe lease amendment reduces leased space and is expected to cut aggregate lease payments by roughly $33.9M, materially lowering ongoing facility costs and long-term obligations. Reduced operating leverage improves cash burn profile and allows reallocation of capital toward core development programs.
Focused Clinical-stage PipelineA refocused pipeline concentrated on SER-155 (Phase 2–ready) and SER-603 (IND-enabling) narrows development focus and resource needs. Upcoming investigator-sponsored SER-155 data offers a near-term clinical de-risking opportunity and could attract partners to fund pivotal work.
Bears Say
Persistent High Cash BurnTTM operating cash flow and free cash flow near -$42M reflect sustained negative cash generation. Ongoing high burn necessitates frequent external financing or asset sales, elevating dilution and execution risk and constraining the company's ability to fund multi-year clinical development independently.
Elevated Leverage Limits FlexibilityA roughly 3.0x debt-to-equity profile leaves Seres with elevated leverage and reduced financial flexibility. High debt increases refinancing and covenant risk, raises fixed obligations, and narrows strategic options if clinical timelines slip or capital markets tighten, pressuring long-term stability.
Early-stage Revenue; Negative MarginsAlthough revenue rebounded to $1.1M, the business still records negative gross profit and deep operating losses (~-$87.6M EBIT). The expense base is not supported by current revenues, indicating structural margin risk until commercial-scale sales, approvals, or partnered commercialization are achieved.
Seres Therapeutics News
MCRB FAQ
What was Seres Therapeutics Inc.’s price range in the past 12 months?
Seres Therapeutics Inc. lowest stock price was $6.32 and its highest was $29.98 in the past 12 months.
What is Seres Therapeutics Inc.’s market cap?
Seres Therapeutics Inc.’s market cap is $64.20M.
When is Seres Therapeutics Inc.’s upcoming earnings report date?
Seres Therapeutics Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 57 days.
How were Seres Therapeutics Inc.’s earnings last quarter?
Seres Therapeutics Inc. released its earnings results on May 05, 2026. The company reported -$2.08 earnings per share for the quarter, missing the consensus estimate of -$1.88 by -$0.2.
Is Seres Therapeutics Inc. overvalued?
According to Wall Street analysts Seres Therapeutics Inc.’s price is currently Undervalued.
Does Seres Therapeutics Inc. pay dividends?
Seres Therapeutics Inc. does not currently pay dividends.
What is Seres Therapeutics Inc.’s EPS estimate?
Seres Therapeutics Inc.’s EPS estimate is -2.3.
How many shares outstanding does Seres Therapeutics Inc. have?
Seres Therapeutics Inc. has 9,683,934 shares outstanding.
What happened to Seres Therapeutics Inc.’s price movement after its last earnings report?
Seres Therapeutics Inc. reported an EPS of -$2.08 in its last earnings report, missing expectations of -$1.88. Following the earnings report the stock price went down -2.471%.
Which hedge fund is a major shareholder of Seres Therapeutics Inc.?
Currently, no hedge funds are holding shares in MCRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Seres Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.00 (147.47% Upside)
$22.00 (147.47% Upside)
Blogger Sentiment
Bullish
MCRB Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.67%
12-Months-Change
Fundamentals
Return on Equity
-127.30%
Trailing 12-Months
Asset Growth
-28.36%
Trailing 12-Months
Company Description
Seres Therapeutics Inc.
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.
MCRB Stock 12 Month Forecast
Average Price Target
$22.00
▲(147.47% Upside)
Technical Analysis
Anixa Biosciences
―
Surrozen
―
Cognition Therapeutics
―
Immix Biopharma
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
1.16% Insiders
4.32% Mutual Funds
12.28% Other Institutional Investors
77.97% Public Companies and
Individual Investors